EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)
Go back to EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)| Regeneron (NASDAQ: REGN) | Delayed: 612.50 +2.56 (0.42%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $609.94 | 52 Week High | $592.36 | |||
| Open | $604.46 | 52 Week Low | $325.35 | |||
| Day High | $613.56 | P/E | 160.76 | |||
| Day Low | $594.90 | EPS | $3.81 | |||
| Volume | 1,604,280 | |||||
